ERIS Lifesciences Ltd News
Eris Lifesciences Q2FY25 results: Profit skids 25.8%, revenue up 46.6%
The decline in PAT can be partly attributed to the deferred tax credit of Rs 21 crore, which the company received in the year-ago quarter
 "Eris Lifesciences Q2FY25 results: Profit skids 25.8%, revenue up 46.6%")
Eris Lifesciences Q2 results: Net profit declines 20% to Rs 97 crore
Eris Lifesciences on Friday said its consolidated profit after tax declined 20 per cent year-on-year to Rs 97 crore in the September quarter. The drug firm had reported a Profit After Tax (PAT) of Rs 122 crore in the July-September period of last fiscal. Revenue increased to Rs 741 crore in the second quarter compared to Rs 505 crore in the year-ago period, the company said in a statement. "The acquired businesses of Biocon and Swiss Parenterals have been integrated and are scaling up in line with our expectations," Eris Lifesciences Chairman and Managing Director Amit Bakshi said. The company is on track to achieve revenue guidance of Rs 2,600 crore in domestic formulations and Rs 3,000 crore on a consolidated basis, he added. "We continue building up our capabilities in the biologics segment. With a strategic investment in Levim Lifetech, we will become a vertically integrated Biotech player with capabilities across the value chain," Bakshi said. Shares of the company settled 0
 "Eris Lifesciences Q2 results: Net profit declines 20% to Rs 97 crore")
Aster DM, Laurus Labs among 5 smallcap stock ideas in a falling market
Eris Lifesciences, BLS International and Five-Star Business are the other 3 smallcap stocks that look favourably placed on the technical charts in an otherwise weak market.
 "Aster DM, Laurus Labs among 5 smallcap stock ideas in a falling market")
ChrysCapital exits Eris Lifesciences; sells 7.27% stake for Rs 1,187 cr
Private equity major ChrysCapital on Thursday exited Eris Lifesciences by selling its entire 7.27 per cent stake in the company for Rs 1,187 crore via open market transaction, while Infinity Partners picked up shares of the firm. Eris Lifesciences Ltd is a listed Indian pharmaceutical company and a leading player in the domestic branded formulations market. According to the block deal data available on the National Stock Exchange (NSE), ChrysCapital through its affiliate Emerald Investment Ltd sold 98,86,882 shares, amounting to a 7.27 per cent stake in Ahmedabad-based Eris Lifesciences. The shares were disposed of at an average price of Rs 1,201 apiece, taking the transaction value to Rs 1,187.41 crore. These shares were picked up by Infinity Partners at the same price, as per the data on the exchange. Shares of Eris Lifesciences rose 2.13 per cent to close at Rs 1,238.65 apiece on the NSE. Earlier this month, Eris Lifesciences said its consolidated profit after tax declined by
 "ChrysCapital exits Eris Lifesciences; sells 7.27% stake for Rs 1,187 cr")
